Literature DB >> 24362678

Evidences for B6C3-Tg (APPswe/PSEN1dE9) double-transgenic mice between 3 and 10 months as an age-related Alzheimer's disease model.

Zhiyong Zhong1, Lin Yang, Xiansheng Wu, Wei Huang, Jiarong Yan, Shenglai Liu, Xia Sun, Ke Liu, Huangquan Lin, Shaosong Kuang, Xiaojiang Tang.   

Abstract

Transgenic mouse has shown great advantages in the study of Alzheimer's disease (AD) and drug screening as AD develops rapidly resent years, while more detail information of these transgenic mice and experience of application are needed. To obtain the basic background information of the B6C3-Tg (APPswe/PSEN1dE9) double-transgenic mouse, which was reported with early onset AD, three- to ten-month-old B6C3-Tg AD mice and normal C57BL/6 mice were selected randomly to test the ability of learning memory by Morris water maze, the brain acetylcholinesterase (AChE) activity by AChE kit, and beta amyloid protein level by immunohistochemistry staining. Compared with the control group, the escape latency time of B6C3-Tg AD mice at 9 and 10 months of age is significantly longer (P < 0.05) in Morris maze test, and the activity of brain AChE is higher. β-Amyloid plaques were observed at 3 months of age and developed rapidly. Statistical analysis showed a positive correlation between the area of these plaques and the ages of B6C3-Tg AD mouse (y = 0.0355e(0.5557x), R = 0.9557). The model's behavior is conformed to simulate behaviors of human Alzheimer's disease at the early stage and may provide detail background information a new choice when transgenic mice are needed in the research of AD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24362678     DOI: 10.1007/s12031-013-0203-5

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  17 in total

Review 1.  Transgenic mouse models of Alzheimer's disease.

Authors:  B J Hock; B T Lamb
Journal:  Trends Genet       Date:  2001-10       Impact factor: 11.639

2.  Co-expression of multiple transgenes in mouse CNS: a comparison of strategies.

Authors:  J L Jankowsky; H H Slunt; T Ratovitski; N A Jenkins; N G Copeland; D R Borchelt
Journal:  Biomol Eng       Date:  2001-06

Review 3.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

4.  Forecasting the global burden of Alzheimer's disease.

Authors:  Ron Brookmeyer; Elizabeth Johnson; Kathryn Ziegler-Graham; H Michael Arrighi
Journal:  Alzheimers Dement       Date:  2007-07       Impact factor: 21.566

Review 5.  Alzheimer disease pharmacologic treatment and treatment research.

Authors:  Lon S Schneider
Journal:  Continuum (Minneap Minn)       Date:  2013-04

Review 6.  Targeting acetylcholinesterase and butyrylcholinesterase in dementia.

Authors:  Roger M Lane; Steven G Potkin; Albert Enz
Journal:  Int J Neuropsychopharmacol       Date:  2005-08-05       Impact factor: 5.176

Review 7.  New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.

Authors:  Salvatore Salomone; Filippo Caraci; Gian Marco Leggio; Julia Fedotova; Filippo Drago
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

Review 8.  Genes, models and Alzheimer's disease.

Authors:  P F Chapman; A M Falinska; S G Knevett; M F Ramsay
Journal:  Trends Genet       Date:  2001-05       Impact factor: 11.639

9.  Role of caspase-3 in tau truncation at D421 is restricted in transgenic mouse models for tauopathies.

Authors:  Qipeng Zhang; Xiaoguang Zhang; Jie Chen; Yanying Miao; Anyang Sun
Journal:  J Neurochem       Date:  2009-02-05       Impact factor: 5.372

10.  Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex.

Authors:  T Rees; P I Hammond; H Soreq; S Younkin; S Brimijoin
Journal:  Neurobiol Aging       Date:  2003-10       Impact factor: 4.673

View more
  9 in total

1.  Mitochondrial Sirt3 Expression is Decreased in APP/PS1 Double Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Wenxiu Yang; Yan Zou; Man Zhang; Nan Zhao; Qi Tian; Min Gu; Wei Liu; Rui Shi; Yang Lü; Weihua Yu
Journal:  Neurochem Res       Date:  2015-06-05       Impact factor: 3.996

2.  The Protective Effects of Osteocyte-Derived Extracellular Vesicles Against Alzheimer's Disease Diminished with Aging.

Authors:  Ya-Ling Jiang; Zhen-Xing Wang; Xi-Xi Liu; Mei-Dan Wan; Yi-Wei Liu; Bin Jiao; Xin-Xin Liao; Zhong-Wei Luo; Yi-Yi Wang; Chun-Gu Hong; Yi-Juan Tan; Ling Weng; Ya-Fang Zhou; Shan-Shan Rao; Jia Cao; Zheng-Zhao Liu; Teng-Fei Wan; Yuan Zhu; Hui Xie; Lu Shen
Journal:  Adv Sci (Weinh)       Date:  2022-05-04       Impact factor: 17.521

3.  Intracerebral Injection of Extracellular Vesicles from Mesenchymal Stem Cells Exerts Reduced Aβ Plaque Burden in Early Stages of a Preclinical Model of Alzheimer's Disease.

Authors:  Chiara A Elia; Matteo Tamborini; Marco Rasile; Genni Desiato; Sara Marchetti; Paolo Swuec; Sonia Mazzitelli; Francesca Clemente; Achille Anselmo; Michela Matteoli; Maria Luisa Malosio; Silvia Coco
Journal:  Cells       Date:  2019-09-10       Impact factor: 6.600

4.  MG53 protein rejuvenates hUC-MSCs and facilitates their therapeutic effects in AD mice by activating Nrf2 signaling pathway.

Authors:  Shanshan Ma; Xinkui Zhou; Yaping Wang; Zhe Li; Yingying Wang; Jijing Shi; Fangxia Guan
Journal:  Redox Biol       Date:  2022-04-30       Impact factor: 10.787

5.  Locomotor Hyperactivity in the Early-Stage Alzheimer's Disease-like Pathology of APP/PS1 Mice: Associated with Impaired Polarization of Astrocyte Aquaporin 4.

Authors:  Tianqi Wang; Yan Chen; Ying Zou; Yingting Pang; Xiaoxin He; Yali Chen; Yun Liu; Weixi Feng; Yanli Zhang; Qian Li; Jingping Shi; Fengfei Ding; Charles Marshall; Junying Gao; Ming Xiao
Journal:  Aging Dis       Date:  2022-10-01       Impact factor: 9.968

6.  Studying the Specific Activity of the Amide Form of HLDF-6 Peptide using the Transgenic Model of Alzheimer's Disease.

Authors:  A P Bogachouk; Z I Storozheva; G B Telegin; A S Chernov; A T Proshin; V V Sherstnev; Yu A Zolotarev; V M Lipkin
Journal:  Acta Naturae       Date:  2017 Jul-Sep       Impact factor: 1.845

7.  Semi-automatic synthesis and biodistribution of N-(2-18F-fluoropropionyl)-bis(zinc (II)-dipicolylamine) (18F-FP-DPAZn2) for AD model imaging.

Authors:  Fuhua Wen; Dahong Nie; Kongzhen Hu; Ganghua Tang; Shaobo Yao; Caihua Tang
Journal:  BMC Med Imaging       Date:  2017-04-21       Impact factor: 1.930

8.  Plasmon-Activated Water Reduces Amyloid Burden and Improves Memory in Animals with Alzheimer's Disease.

Authors:  Chia-Hsiung Cheng; Kun-Ju Lin; Chien-Tai Hong; Dean Wu; Hung-Ming Chang; Cheng-Huan Liu; Ing-Tsung Hsiao; Chih-Ping Yang; Yu-Chuan Liu; Chaur-Jong Hu
Journal:  Sci Rep       Date:  2019-09-13       Impact factor: 4.379

9.  Therapeutic efficacy of novel memantine nitrate MN-08 in animal models of Alzheimer's disease.

Authors:  Liangmiao Wu; Xinhua Zhou; Yiwan Cao; Shing Hung Mak; Ling Zha; Ning Li; Zhiyang Su; Yifan Han; Yuqiang Wang; Maggie Pui Man Hoi; Yewei Sun; Gaoxiao Zhang; Zaijun Zhang; Xifei Yang
Journal:  Aging Cell       Date:  2021-05-06       Impact factor: 9.304

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.